Previous 10 | Next 10 |
DBV Technologies S.A. (DBVT) Q4 2022 Results Conference Call March 02, 2023 05:00 PM ET Company Participants Anne Pollak - Head IR Daniel Tassé - CEO Sébastien Robitaille - CFO Pharis Mohideen - Chief Medical Officer Conference Call Participants ...
Montrouge, France, March 2, 2023 DBV Techn ologies a nnounces f iling of 202 2 Annual Report on Form 10-K and 202 2 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBV...
DBV Technologies press release ( NASDAQ: DBVT ): Q4 GAAP EPS of -$1.24. Revenue of $4.8M (-15.8% Y/Y). For further details see: DBV Technologies GAAP EPS of -$1.24, revenue of $4.8M
Montrouge, France, March 2, 2023 DBV Technologies Reports Full Year 2022 Financial Results and Business Update DBV completed EVOLVE, a 12-week caregiver and patient user experience study of the modified Viaskin Peanut patch in peanut-allergic children ages 4 – 11 years old ...
Montrouge, France, February 27, 2023 DBV Technologies to Report Full Year 202 2 Financial Results and Business Updates on March 2 , 202 3 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharma...
Montrouge, France, February 21, 2023 DBV Technologies to Participate in Upcoming AAAAI 2023 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at t...
Montrouge, France, February 10, 2023 DBV Technologies t o Participate i n Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its parti...
Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of Dec em ber 3 1 , 202 2 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Mark...
Summary I explain why I've added Organigram to my tax loss selling basket. I also review the company's performance and risks. Finally, I recap my entire 2022 tax loss selling basket of stocks, some of which I didn't have time to write up individually. Tax Loss Selling Strategy...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutic...
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expecte...
Châtillon, France, July 29, 2024 DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, toda...